Future prospects for regenerated heart using induced pluripotent stem cells

Jun Fujita, Keiichi Fukuda

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Induced pluripotent stem cell (iPSC) generation is an epoch-making technology. The potential applications for iPSCs are wide-ranging from in vitro disease models to drug discovery. For regenerative medicine in particular, the technology provides great hope for patients with incurable diseases or potentially fatal disorders such as heart failure (HF). However, the true realization of that promise for HF remains uncertain and moving toward the clinical application of iPSCs needs to be stepwise and careful. The establishment of "safe" iPSCs must be a major premise, while genome integration-free and oncogene-free reprogramming is also necessary. Teratoma formation also remains a risk with undifferentiated iPSCs, but it must not happen in patients' bodies. Thus, regardless of the target organ, the differentiated cells from iPSCs must be purified to exclude any possibility of tumorigenicity. The transplantation strategies used for iPSC-derived cells are very important for the recovery of lost cardiac function. Longer engraftment of transplanted iPSCs-derived cardiomyocytes is essential particularly because their survival could be hampered by ischemia, inflammation, apoptosis, immunological rejection, and other cardiac phenomena. Providing these multistep solutions will open the new frontier of regenerative therapies with iPSCs for patients with severe HF.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalJournal of Pharmacological Sciences
Volume125
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Induced Pluripotent Stem Cells
Heart Failure
Technology
Regenerative Medicine
Teratoma
Drug Discovery
Oncogenes
Cardiac Myocytes
Ischemia
Transplantation
Genome
Apoptosis
Inflammation
Survival
Therapeutics

Keywords

  • Cardiomyocyte
  • Cell survival
  • Cell transplantation
  • Induced pluripotent stem cell
  • Regenerative medicine

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Future prospects for regenerated heart using induced pluripotent stem cells. / Fujita, Jun; Fukuda, Keiichi.

In: Journal of Pharmacological Sciences, Vol. 125, No. 1, 2014, p. 1-5.

Research output: Contribution to journalArticle

@article{9eaac5d57e0543968e26ed24195a7143,
title = "Future prospects for regenerated heart using induced pluripotent stem cells",
abstract = "Induced pluripotent stem cell (iPSC) generation is an epoch-making technology. The potential applications for iPSCs are wide-ranging from in vitro disease models to drug discovery. For regenerative medicine in particular, the technology provides great hope for patients with incurable diseases or potentially fatal disorders such as heart failure (HF). However, the true realization of that promise for HF remains uncertain and moving toward the clinical application of iPSCs needs to be stepwise and careful. The establishment of {"}safe{"} iPSCs must be a major premise, while genome integration-free and oncogene-free reprogramming is also necessary. Teratoma formation also remains a risk with undifferentiated iPSCs, but it must not happen in patients' bodies. Thus, regardless of the target organ, the differentiated cells from iPSCs must be purified to exclude any possibility of tumorigenicity. The transplantation strategies used for iPSC-derived cells are very important for the recovery of lost cardiac function. Longer engraftment of transplanted iPSCs-derived cardiomyocytes is essential particularly because their survival could be hampered by ischemia, inflammation, apoptosis, immunological rejection, and other cardiac phenomena. Providing these multistep solutions will open the new frontier of regenerative therapies with iPSCs for patients with severe HF.",
keywords = "Cardiomyocyte, Cell survival, Cell transplantation, Induced pluripotent stem cell, Regenerative medicine",
author = "Jun Fujita and Keiichi Fukuda",
year = "2014",
doi = "10.1254/jphs.14R01CP",
language = "English",
volume = "125",
pages = "1--5",
journal = "Journal of Pharmacological Sciences",
issn = "1347-8613",
publisher = "Japanese Pharmacological Society",
number = "1",

}

TY - JOUR

T1 - Future prospects for regenerated heart using induced pluripotent stem cells

AU - Fujita, Jun

AU - Fukuda, Keiichi

PY - 2014

Y1 - 2014

N2 - Induced pluripotent stem cell (iPSC) generation is an epoch-making technology. The potential applications for iPSCs are wide-ranging from in vitro disease models to drug discovery. For regenerative medicine in particular, the technology provides great hope for patients with incurable diseases or potentially fatal disorders such as heart failure (HF). However, the true realization of that promise for HF remains uncertain and moving toward the clinical application of iPSCs needs to be stepwise and careful. The establishment of "safe" iPSCs must be a major premise, while genome integration-free and oncogene-free reprogramming is also necessary. Teratoma formation also remains a risk with undifferentiated iPSCs, but it must not happen in patients' bodies. Thus, regardless of the target organ, the differentiated cells from iPSCs must be purified to exclude any possibility of tumorigenicity. The transplantation strategies used for iPSC-derived cells are very important for the recovery of lost cardiac function. Longer engraftment of transplanted iPSCs-derived cardiomyocytes is essential particularly because their survival could be hampered by ischemia, inflammation, apoptosis, immunological rejection, and other cardiac phenomena. Providing these multistep solutions will open the new frontier of regenerative therapies with iPSCs for patients with severe HF.

AB - Induced pluripotent stem cell (iPSC) generation is an epoch-making technology. The potential applications for iPSCs are wide-ranging from in vitro disease models to drug discovery. For regenerative medicine in particular, the technology provides great hope for patients with incurable diseases or potentially fatal disorders such as heart failure (HF). However, the true realization of that promise for HF remains uncertain and moving toward the clinical application of iPSCs needs to be stepwise and careful. The establishment of "safe" iPSCs must be a major premise, while genome integration-free and oncogene-free reprogramming is also necessary. Teratoma formation also remains a risk with undifferentiated iPSCs, but it must not happen in patients' bodies. Thus, regardless of the target organ, the differentiated cells from iPSCs must be purified to exclude any possibility of tumorigenicity. The transplantation strategies used for iPSC-derived cells are very important for the recovery of lost cardiac function. Longer engraftment of transplanted iPSCs-derived cardiomyocytes is essential particularly because their survival could be hampered by ischemia, inflammation, apoptosis, immunological rejection, and other cardiac phenomena. Providing these multistep solutions will open the new frontier of regenerative therapies with iPSCs for patients with severe HF.

KW - Cardiomyocyte

KW - Cell survival

KW - Cell transplantation

KW - Induced pluripotent stem cell

KW - Regenerative medicine

UR - http://www.scopus.com/inward/record.url?scp=84902182234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902182234&partnerID=8YFLogxK

U2 - 10.1254/jphs.14R01CP

DO - 10.1254/jphs.14R01CP

M3 - Article

C2 - 24739283

AN - SCOPUS:84902182234

VL - 125

SP - 1

EP - 5

JO - Journal of Pharmacological Sciences

JF - Journal of Pharmacological Sciences

SN - 1347-8613

IS - 1

ER -